Combatting The 'Bad Trip': New Research Project Seeks Solutions That Go Beyond Psychedelics
Ehave, Inc. (OTC:EHVVF) has completed the first of three planned phases of its studies with the University of Melbourne to determine the cause and possible cure for hallucinogen-persisting perception
Ehave Provides Progress Update on Its HPPD Study With University of Melbourne
Potential of monetizing HPPD research by identifying biomarkers to identify individuals who have a higher risk of developing HPPD if they take psychedelicsMIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Eh
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
After a full review of healthcare provider Ehave Inc.'s (OTC:EHVVF) IND application, the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with a clinical trial assessing l
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
Ehave study "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder" a
Press Release: Ehave Shareholder From CEO Ben Kaplan and Corporate Update
Ehave Shareholder from CEO Ben Kaplan and Corporate Update MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in t
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treat
Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research
AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individ
Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
Mycotopia Therapies (OTCPK:TPIA) subsidiary of Ehave, Inc. (OTCPK:EHVVF), has signed a definitive agreement to complete a triangular merger with Ei.Ventures, to form PSLY.COM. The companies anticipate
Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies valued at more than $24 million, as of Friday's closing price; Plans partial distribution to shareholdersMIAMI, May 23, 2022 (GLOBE N
Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD
MIAMI, April 19, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a leading healthcare services and technology company, announced today its MetaHealthU mobile application plat
Ehave Continues Expansion Of KetaDASH Mobile Psychedelic Service By Providing Licensed Psychotherapists And Registered Nurses
Agreement with Heally adds doctors, licensed psychotherapists and registered nurses to the KetaDASH platformWith the opening of KetaDASH, Ehave builds momentum for the psychedelic renaissance in the m
KetaDASH Announces Mobile Ketamine Treatments in San Francisco and Sacramento Area
Ehave, Inc. (OTC:EHVVF), a healthcare company developing digital solutions in the medical cannabis and mental health sectors, reported that its wholly-owned subsidiary, KetaDASH, is offering in-home k
Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV
MIAMI, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a leading healthcare services and technology company, reaffirms its commitment to shareholders to launch its K
Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures
Mycotopia and Ei.Ventures announced the signing of an LOI to explore a merger and the formation of PSLY.COM, a $360 Million transaction, and will apply to list shares on NASDAQ; Ehave plans to spin ou
Robinhood plummeted nearly 7% SEC chairman says discussions are under way to ban order flow payments
The stock price of the US influencer online brokerage firm Robinhood plummeted nearly 7% on Monday. Gary Gensler, chairman of the US Securities and Exchange Commission (SEC), said that the controversial ban on payment for order flow (PFOF) has already been “put on the table.” Gensler told the media that there was an “inherent conflict of interest” in order flow payments, but did not say whether the SEC discovered situations where the conflict of interest caused investors to lose money. Gensler said staff are reviewing this practice and may be there a few days in the future
Pfizer Inc-BioNTech COVID-19 Vaccine recommended by CDC Public Health Advisor of the United States
The COVID-19 vaccine jointly developed by Pfizer Inc and BioNTech SE was recommended by US vaccine consultants after being fully approved by regulators last week, in a move expected to help contain a resurgent epidemic driven by the Delta strain. Fourteen members of the Advisory Committee on Immunization measures of the Centers for Disease Control and Prevention (CDC) voted unanimously on Monday to approve the vaccine for people aged 16 and over. The proposal still needs to be finally signed by Rochelle Walensky, director of CDC. Pfizer Inc-BioNTech vaccine is the first to be fully approved by the Food and Drug Administration (FDA) of the United States.
Ehave Files 6-K Disclosing LOI Details For The Acquisition Of Moksha Digital Software >EHVVF
*DJ Ehave Files 6-K Disclosing LOI Details For The Acquisition Of Moksha Digital Software >EHVVF (MORE TO FOLLOW) Dow Jones Newswires August 25, 2021 09:42 ET (13:42 GMT) Copyright (c) 202
Ehave Accelerates Growth With LOI To Acquire India Based Moksha Digital, A Medical Imaging Software Provider >EHVVF
*DJ Ehave Accelerates Growth With LOI To Acquire India Based Moksha Digital, A Medical Imaging Software Provider >EHVVF (MORE TO FOLLOW) Dow Jones Newswires August 24, 2021 13:49 ET (17:49 G
Us Oil fell nearly 4% to step back on 65%, and the rebound of the epidemic overshadowed the prospect of demand recovery.
The original title: us oil fell nearly 4%, want to step back 65%, the rebound of the epidemic clouded the prospect of demand recovery on Monday (August 9), US oil continued the sharp decline last week, falling nearly 4%, due to the rising US dollar. And the market is worried that the introduction of new epidemic control measures in Asia may hinder the recovery of global fuel demand. As of press time, the futures price of US crude oil was down 3.79% at US $65.25 per barrel, while the futures price of Brent crude oil was at US $67.75 per barrel, down 4.17%. Last week, US oil fell nearly 7%, the biggest weekly decline in nine months, and Brent crude oil futures fell 6% to 4%.
"July crash"! The United States COVID-19 confirmed cases surged the Dow plunged more than 800 points, the market may fall 20%?
FX168 Financial News (North America) due to fears that the rebound in COVID-19 infection cases will slow global economic growth, the U. S. stock market fell sharply on Monday. The sell-off has increased over time, and the Dow is on track to record its biggest decline so far this year. In the U.S., the Dow fell 777 points, or 2.2%, after falling more than 800 points earlier, more than the 2% drop at the end of January. The s & p 500 fell 1.9%, with energy and industrials among the worst performers. The Nasdaq composite index fell 1.6%. (photo Source: Zerohedge) known as "fear"
No Data